Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | NRP1 | O14786 | 5/20 | 0.34 |
| ▸ | ERN1 | O75460 | 3/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.32 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.32 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.31 |
| ▸ | PTPRC | P08575 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | LOX | P28300 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4646451 | 0.78 | NRP1 (0.33) | NRP1ERN1PARP1CYP2A6 | |
| SCHEMBL4645575 | 0.78 | MAPT (0.38) | NRP1ERN1PARP1 | |
| SCHEMBL4648553 | 0.78 | PARP1 (0.41) | NRP1ERN1PARP1 | |
| SCHEMBL4647459 | 0.78 | PARP1 (0.34) | NRP1PARP1 | |
| SCHEMBL4648162 | 0.77 | NRP1 (0.40) | NRP1PARP1 | |
| SCHEMBL4736511 | 0.77 | ACMSD (0.50) | CHEK2GLO1ACMSDPARP1CHEK1 | |
| SCHEMBL4647930 | 0.76 | PDE4B (0.40) | NRP1PARP1 | |
| SCHEMBL4648583 | 0.75 | ERN1 (0.40) | ERN1CYP2A6 | |
| SCHEMBL4647763 | 0.75 | HSD17B1 (0.37) | NRP1PARP1 | |
| SCHEMBL4648578 | 0.75 | KIF11 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255117-A1 | SULFONYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-10-16 | — | — | US | claimed |
| WO-2008104597-A2 | SULFONYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | WO | claimed |
| EP-1964834-A1 | Sulphonyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-09-03 | — | — | EP | claimed |
| US-20080255117-A1 | SULFONYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-10-16 | — | — | US | disclosed |
| WO-2008104597-A2 | SULFONYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | WO | disclosed |
| EP-1964834-A1 | Sulphonyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255117-A1 | SULFONYLTRYPTOPHANOLS | FSHR, NPY1R, GNRHR | GRIA2 1038/4885NRP1 2591/4885ERN1 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.